© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > “compound 25”
<< Back to February
mutant KRASG12C allosteric covalent inhibitor
orally efficacious in XG model
from optimization of literature starting point
J. Med. Chem. Feb. 5, 2020
AstraZeneca, Cambridge, UK
KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)
Unlock this content with a Premium membership to read it now.